An interventional study of Periodic, over-the-counter continuous glucose monitoring in Type 2 Diabetes and Non Insulin Dependent Diabetes, sponsored by University of Colorado, Denver. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-29.
Sponsored by University of Colorado, Denver · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies in Diabetes Mellitus, Type 2 by University of Colorado, Denver — 6 open to participants now, 8 under way, none of them phase 3. Diabetes Mellitus, Type 2 · University of Colorado, Denver.
Among the 41 studies in Diabetes Mellitus, Type 2 by University of Colorado, Denver, this one is the 8th largest by planned enrollment of the 33 interventional ones that give a count, is one of 3 that started in 2026, is one of 26 with no phase, and was the 41st registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →6 of the 41 studies in Diabetes Mellitus, Type 2 by University of Colorado, Denver are open now, in 1 country. Recruiting first, the newest first:
University of Colorado, Denver · Sites in United States
Ages 14–24
University of Colorado, Denver · Sites in United States
Ages 18–89
University of Colorado, Denver · Sites in United States
Ages 30–55 · Healthy volunteers
University of Colorado, Denver · Sites in United States
Ages 18–65
University of Colorado, Denver · Sites in United States
Ages 12–17
By country, each count listing its studies:
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 4 2
First in 2002; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 188 is above the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 62 across the 33 interventional studies, 50 across the 8 observational. Of the 31 that completed or were terminated, 11 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Colorado, Denver is the lead sponsor of 1,547 studies on the registry; 318 are open to participants now.
Of its 148 completed or terminated interventional studies of FDA-regulated products, 93 (63%) have results posted.
3 of the studies in Diabetes Mellitus, Type 2 by University of Colorado, Denver that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05507892University of Colorado, DenverRenal Mechanism of SGLT2 Inhibition | 2026-12-15 |
| NCT04791371University of Colorado, DenverRole of Microvascular Insulin Resistance and Cardiorespiratory Fitness Diabetes | 2027-01-15 |
| NCT07011147University of Colorado, DenverPrimary Care Pragmatic, Real World Experience for Automated Insulin Delivery | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 41 studies in Diabetes Mellitus, Type 2 by University of Colorado, Denver, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if periodic use of over-the-counter continuous glucose monitoring (CGM) can support glucose management in people with type 2 diabetes not using insulin being treated in primary care settings. The main questions it aims to answer are:
Participants will:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Use of periodic, OTC CGM every 30 days for six months.
Device: Periodic, over-the-counter continuous glucose monitoring
Use of periodic, OTC CGM every 90 days for six months.
Device: Periodic, over-the-counter continuous glucose monitoring
Periodic, over-the-counter continuous glucose monitoring for people with non-insulin-treated type 2 diabetes treated in primary care settings.
Change in A1C from baseline to 6 months
Change in A1C from baseline (enrollment) to 6 months.
Time frame: From enrollment to completion of study visits at 6 months
Change in Time in Range from baseline to 6 months
Change in time in range (TIR) collected from patients via blinded Dexcom G7 continuous glucose monitoring from baseline (enrollment) to completion of study visits at 6 months.
Time frame: From enrollment to the completion of study visits at 6 months.
Change in Time in Tight Range from baseline to 6 months
Change in time in tight range (TITR) collected from patients via blinded Dexcom G7 continuous glucose monitoring from baseline (enrollment) to completion of study visits at 6 months.
Time frame: From enrollment to the completion of study visits at 6 months.
Change in mean glucose from baseline to 6 months
Change in mean glucose collected from patients via blinded Dexcom G7 continuous glucose monitoring from baseline (enrollment) to completion of study visits at 6 months.
Time frame: From enrollment to the completion of study visits at 6 months.
Change in TAR (>180) from baseline to 6 months
Change in time above range (\>180 mg/dL) collected from patients via blinded Dexcom G7 continuous glucose monitoring from baseline (enrollment) to completion of study visits at 6 months.
Time frame: From enrollment to the completion of study visits at 6 months.
Change in A1C from baseline to 3 months.
Change in A1C from baseline (enrollment) to 3 months.
Time frame: From enrollment to 3-month study visit
Change in TIR from baseline to 3 months.
Change in TIR from baseline (enrollment) to 3 months.
Time frame: From enrollment to 3-month study visit
Change in TITR from baseline to 3 months.
Change in TITR from baseline (enrollment) to 3 months.
Time frame: From enrollment to 3-month study visit
Change in mean glucose from baseline to 3 months
Change in mean glucose collected from patients via blinded Dexcom G7 continuous glucose monitoring from baseline (enrollment) to the 3-month study visit.
Time frame: From enrollment to 3-month study visit
Change in TAR (>180) from baseline to 3 months
Change in time above range (\>180 mg/dL) collected from patients via blinded Dexcom G7 continuous glucose monitoring from baseline (enrollment) to 3-month study visit.
Time frame: From enrollment to 3-month study visit
Feasibility ratings of periodic, OTC CGM to primary care clinicians
Feasibility of Intervention Measure (FIM) ratings for periodic, over-the-counter continuous glucose monitoring from clinicians in participating practices. FIM items are measured on a Likert scale ranging from (1) Completely disagree to (5) Completely agree. Higher ratings indicate more favorable ratings of intervention feasibility.
Time frame: Two years following practice study enrollment
Acceptability ratings of periodic, OTC CGM to primary care clinicians
Acceptability of Intervention Measure (AIM) ratings for periodic, over-the-counter continuous glucose monitoring from clinicians in participating practices. AIM items are measured on a Likert scale ranging from (1) Completely disagree to (5) Completely agree. Higher ratings indicate more favorable ratings of intervention acceptability.
Time frame: Two years following practice study enrollment
Days of wear of periodic, OTC CGM (Patient Acceptance)
As a proxy for patient acceptance, we will report mean days of wear for over-the-counter continuous glucose monitoring devices, measured using Dexcom Stelo device metrics. Days of wear range from 0 to 15 days per session. Higher mean values reflect greater levels of patient acceptance.
Time frame: Two years following practice study enrollment
Glucose monitoring satisfaction for periodic, OTC CGM (Patient Acceptance)
As a proxy for patient acceptance, we will report patient ratings of satisfaction with periodic, OTC CGM use using the Glucose Monitoring Satisfaction Survey (GMSS). Ratings of GMSS items range from (1) Strongly disagree to (5) Strongly agree, with higher values indicating greater satisfaction.
Time frame: Two years following practice study enrollment
Willingness to pay for periodic, OTC CGM (Patient Acceptance)
As a proxy for patient acceptance, we will report patients' willingness to pay for periodic, OTC CGM as measured by percentage of patients willing to pay up to various dollar amounts. Higher willingness-to-pay values and greater percentages of participants willing to pay at various price points reflect greater patient acceptability.
Time frame: Two years following practice study enrollment
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided — Finalizing data sharing plan for sensitive data sources.
Started Apr 2026 (actual). Primary completion is estimated for Dec 2027, 20 months after the start.
Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 20 months is close to that.
Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Colorado, Denver →